All things considered, while the exact RNA editing mechanism to which CCAT2 is subjected has not yet been uncovered, there is significant evidence pointing towards its role in the modulation of immune signaling in MDS and MPS [35]. The gene discussed is CCAT2; the disease is myelodysplastic syndrome.